Thalidomide: A review of approved and investigational uses

Clinical Therapeutics

Volumn 25, Issue 2, 2003, Pages 342-395

  Matthews, S James ^a   McCoy, Christopher ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adverse events; Pharmacology; Thalidomide; Therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CD8 ANTIGEN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; IRINOTECAN; LENALIDOMIDE; MELPHALAN; MESSENGER RNA; PAMIDRONIC ACID; PREDNISONE; TACROLIMUS; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGITATION; AMENORRHEA; APHTHOUS ULCER; AREA UNDER THE CURVE; ATRIOVENTRICULAR BLOCK; BEHCET DISEASE; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFUSION; CONSTIPATION; CROHN DISEASE; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DEMENTIA; DEPRESSION; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG USE; EOSINOPHILIA; ERYTHEMA; ERYTHEMA NODOSUM LEPROSUM; FACE EDEMA; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HEADACHE; HEART TAMPONADE; HEPATITIS; HOSTILITY; HUMAN; HYPOTHYROIDISM; INCREASED APPETITE; ISCHEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEG EDEMA; LETHARGY; LEUKOCYTOSIS; LEUKOPENIA; LIBIDO DISORDER; MEDLINE; MENSTRUATION DISORDER; MENTAL INSTABILITY; MOOD DISORDER; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; NAIL DISEASE; NEUTROPENIA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PRURITUS; PSYCHOSIS; PUBLICATION; RASH; REVIEW; SARCOIDOSIS; SEDATION; SEIZURE; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN INFLAMMATION; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNCOPE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VERTIGO; VISUAL DISORDER; WALDENSTROEM MACROGLOBULINEMIA; WASTING SYNDROME; WEIGHT GAIN; XEROSTOMIA;

EID: 0037291745     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80085-1     Document Type: Review

References (222)

1. Tansey EM. Dark Remedy. The Impact of Thalidomide and Its Revival as a Vital Medicine. Book review. N Engl J Med. 2001;345:226-227.
2. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358. Case report.
3. Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962;1:45. Case report.
4. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
5. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis. 1969;37:135-146.
6. Thalomid capsules [package insert]. Warren, NJ: Celgene Corporation; 2001.
7. Eriksson T, Björkman S, Roth B, Hoglund P. Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000;52:807-817.
8. Krenn M, Gamcsik MP, Vogelsang GB, et al. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-β-cyclodextrin. J Pharm Sci. 1992;81:685-689.
9. Eriksson T, Björkman S, Roth B, et al. Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality. 1998;10:223-228.
10. Eriksson T, Björkman S. Handling of blood samples for determination of thalidomide. Clin Chem. 1997;43:1094-1096.
11. Lyon AW, Duran G, Raisys VA. Determination of thalidomide by high performance liquid chromatography: Methodological strategy for clinical trials. Clin Biochem. 1995;28:467-470.
12. Eriksson T, Björkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality. 1995;7:44-52.
13. Teo SK, Colburn WA, Thomas SD. Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol. 1999;39:1162-1168.
14. Trapnell CB, Donahue SR, Collins JM, et al. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 1998;64:597-602.
15. Scheffler MR, Colburn W, Kook KA, Thomas SD. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. Clin Pharmacol Ther. 1999;65:483-490.
16. Noormohamed FH, Youle MS, Higgs CJ, et al. Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res Hum Retroviruses. 1999;15:1047-1052.
17. Teo SK, Scheffler MR, Kook KA, et al. Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol. 2001;41:662-667.
18. Teo SK, Scheffler MR, Kook KA, et al. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm Drag Dispos. 2000;21:33-40.
19. Aweeka F, Trapnell C, Chernoff M, et al, for the AIDS Clinical Trials Group. Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG Protocol 251. J Clin Pharmacol. 2001;41:1091-1097.
20. Wohl DA, Aweeka FT, Schmitz J, et al. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis. 2002;185:1359-1363.
21. Heney D, Norfolk DR, Wheeldon J, et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol. 1991;78:23-27.
22. Boughton BJ, Sheehan TM, Wood J, et al. High-performance liquid chromatographic assay of plasma thalidomide: Stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem. 1995;32:79-83.
23. Eriksson T, Wallin R, Höglund P, et al. Low bioavailability of rectally administered thalidomide. Am J Health Syst Pharm. 2000;57:1607-1610.
24. Teo SK, Harden JL, Burke AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 2001;29:1355-1357.
25. Teo SK, Sabourin PJ, O'Brien K, et al. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14:140-147.
26. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol. 1965;25:338-351
27. Williams RT, Schumacher H, Fabro S, Smith RL. The chemistry and metabolism of thalidomide. In: Robson JM, Sullivan FM, Smith RL, eds. Symposium on Embryopathic Activity of Drugs. London: J and A Churchill; 1965:S167-S182.
28. Somers GF. Pharmacologic properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol. 1960;15:111-116.
29. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
30. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
31. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168:408-414.
32. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:247-257.
33. Jacobson JM, Greenspan JS, Spritzler J, et al, for the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997;336:1487-1493.
34. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1997;13:1047-1054.
35. Marriott JB, Westby M, Cookson S, et al. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol. 1998;161:4236-4243.
36. Prehn JL, Landers C, Muller GW, et al. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol. 2001;21:357-364.
37. Sampaio EP, Hernandez MO, Carvatho DS, Sarno EN. Management of erythema nodosum leprosum by thalidomide: Thalidomide analogues inhibit M. leprae-induced TNF α production in vitro. Biomed Pharmacother. 2002;56:13-19.
38. Klausner JD, Kaplan G, Haslett PA. Thalidomide in toxic epidermal necrolysis. Lancet. 1999;353:324. Letter
39. Letter. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002;50:196-200.
40. Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15:1169-1179.
41. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160-167.
42. Verbon A, Juffermans NP, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother. 2000;44:2286-2290.
43. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol. 1984;11:814-819.
44. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res. 1980;269:275-280.
45. Settles B, Stevenson A, Wilson K, et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand). 2001;47:1105-1114.
46. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev. 1985;56:35-39.
47. Hanekom WA, Hughes J, Haslett PA, et al. The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children. J Infect Dis. 2001;184:1192-1196.
48. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
49. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 1998;55:1827-1834.
50. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal anglogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998;236:461-466.
51. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111-3116.
52. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
53. Tosi P, Ronconi S, Zamagni E, et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica. 2001;86:409-413.
54. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol. 2001;115:605-608.
55. Dmoszynska A, Bojarska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma. 2002;43:401-406.
56. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem. 2001;276:22382-22387.
57. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
58. Payvandi F, Wu L, Haley M, et al. Thalidomide analogs IMiDs inhibit expression of cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated PBMCs. Blood. 2001;98:641a. Abstract 2689.
59. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
60. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31:213-221.
61. Browne SG. Erythema nodosum in leprosy. J Chronic Dis. 1963;16:23-30.
62. Hastings RC, Trautman JR, Enna CD, Jacobsson RR. Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin Pharmacol Ther. 1970;11:481-487.
63. Nogueira AC, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. 1994;55:77-92.
64. Iyer CG, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45:719-732.
65. Waters MF. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev. 1971;42:26-42.
66. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol. 1980;19:318-322.
67. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7:265-273.
68. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol. 1998;134:602-612.
69. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-1058.
70. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604-3609.
71. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000;26:865-869.
72. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant. 1998;21:577-581.
73. Cole CH, Rogers PC, Pritchard S, et al. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant. 1994;14:937-942.
74. Mehta P, Kedar A, Graham-Pole J, et al. Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature. Pediatrics. 1999;103:E44.
75. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol Blood Marrow Transplant. 1996;2:86-92.
76. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96:3995-3996.
77. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108:461-466.
78. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000;39:218-222.
79. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients. Br J Rheumatol. 1997;36:353-359.
80. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol. 2000;39:383-388.
81. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993;11:487-493.
82. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995;32:866-869.
83. Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol. 1998;134:1045-1046.
84. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102:225-236.
85. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol. 2000;97:109-120.
86. Lovell CR, Hawk JLM, Calnan CD, Magnus JA. Thalidomide in actinic prurigo. Br J Dermatol. 1983;108:467-471.
87. Ferrándiz C, Carrascosa JM, Just M, et al. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology. 1997;195:359-361.
88. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme. Br J Dermatol. 1992;126:92-93.
89. Dereure O, Basset-Seguin N, Guilhou JJ. Erosive lichen planus: Dramatic response to thalidomide. Arch Dermatol. 1996;132:1392-1393.
90. George SJ, Hsu S. Lichen planopilaris treated with thalidomide. J Am Acad Dermatol. 2001;45:965-966.
91. Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. Nephron. 1994;67:270-273.
92. Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc. 2000;75:842-844.
93. Guillaume JC, Moulin G, Dieng MT, et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol. 1995;131:1032-1035.
94. Thomas L, Ducros B, Secchi T, et al. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol. 1993;129:1261-1264.
95. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-1589.
96. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a Phase 2 study of 169 patients. Blood. 2001;98:492-494.
97. Grosbois B, Bellissant E, Moreau P, et al. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. Blood. 2001;98:163a. Abstract 689.
98. Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 2000;108:391-393.
99. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001;86:404-408.
100. Bladé J, Esteve J, Rosiñol L, et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol. 2001;28:588-592.
101. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. 2002;87:408-414.
102. Wechalekar AD, Sutton D, Voralia M, et al. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Blood. 2001;98:162a. Abstract 684.
103. Rajkumar SV, Dispenzieri A, Lacy M, et al. Response rate and durability of response with thalidomide therapy for relapsed multiple myeloma (MM). Blood. 2001;98:162a. Abstract 685.
104. Durie BGM, Stepan DE. Low dose thalidomide alone and in combination: Long term follow-up. Blood. 2001;98:163a. Abstract 688.
105. Ciepluch H, Baran W, Hellmann A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Med Sci Monit. 2002;8:P131-P136.
106. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89-96.
107. Grosbois B, Bellissant E, Muret E, et al. Measurement of seric thalidomide (Thal) level in patients treated for advanced multiple myeloma (MM). Blood. 2001;98:308b. Abstract 4987.
108. Kakimoto T, Hattori Y, Okamoto S, et al. Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. Blood. 2001;98:162a. Abstract 682.
109. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399-403.
110. Weber DM, Rankin K, Gavino M, et al. Thalidomide with dexamethasone for resistant multiple myeloma. Blood. 2000;96:167a. Abstract 719.
111. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991-995.
112. Palumbo A, Giaccone L, Bringhen S, et al. Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma. Blood. 2001;98:162a. Abstract 683.
113. Tosi P, Zamagni E, Cellini C, et al. Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patient with advanced relapsed and refractory multiple myeloma. Blood. 2001;163a. Abstract 687.
114. Weber DM, Gavino M, Delasalle K, et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood. 2001;98:604a. Abstract 2686.
115. Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol. 2001;38:250-259.
116. Alexanian R, Weber DM, Giralt S, et al. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Blood. 2001;98:163a. Abstract 686.
117. Munshi N, Desikan R, Zangari M, et al. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM). Blood. 1999;94(Suppl 1):123a. Abstract 540.
118. Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98:3846-3848.
119. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, et al. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J. 2002;3:43-48.
120. Dimopoulos M, Panayiotidis P, Grigoraki V, et al. Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. Blood. 2001;98:164a. Abstract 692.
121. Offidani M, Mele A, Marconi M, et al. Thalidomide plus melphalan in relapsed-refractory multiple myeloma. Blood. 2001;98:311b. Abstract 5000.
122. Srkalovic G, Karam MA, Trebisky BM, et al. Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and Decadron (MTD). Blood. 2000;96:294b. Abstract 5016.
123. Coleman M, Leonard JP, Nahum K, et al. Non-myelosuppressive therapy with BLT-D (Biaxin®, low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. Blood. 2000;96:167a. Abstract 720.
124. Rajkumar SV, Hayman SR, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). Blood. 2001;98:849a. Abstract 3525.
125. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
126. Richardson PG, Schlossman RL, Hideshima T, et al. A Phase I study of oral CC5013, an immunomodulatory thalidomide (Tha1) derivative, in patients with relapsed and refractory multiple myeloma. Blood. 2001;98:775a. Abstract 3225.
127. Zangari M, Tricot G, Zeldis J, et al. Results of Phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood. 2001;98:775a. Abstract 3226.
128. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596-3601.
129. Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndrome. Leukemia. 2002;16:1-6.
130. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
131. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881-894.
132. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2002;96:3671-3674.
133. Raza A, Lisak L, Dutt D, et al. Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). Blood. 2001;98:273b. Abstract 4830.
134. Raza A, Dutt D, Lisak L, et al. Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS). Blood. 2001;98:273b. Abstract 4831.
135. Steins MB, Padró T, Bieker R, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood. 2002;99:834-839.
136. Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:78-83.
137. Tefferi A, Elliott MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood. 2000;96:4007. Letter.
138. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117:288-296.
139. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
140. Stebbing J, Benson C, Eisen T, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer. 2001;85:953-958.
141. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302-306.
142. Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol. 2002;20:1429-1430.
143. Amato RJ, Breheny S, Tracy E, et al. Phase I/II study of thalidomide + interleukin II (IL-2) for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2002;21:190a. Abstract 759.
144. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-715.
145. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma muhiforme. J Neurooncol. 2001;54:31-38.
146. Short SC, Traish D, Dowe A, et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol. 2001;51:41-45.
147. Fine AH, Maher EA, Wen PY, et al. Phase II trial of thalidomide and BCNU in recurrent high-grade gliomas. Proc Am Soc Clin Oncol. 2001;20:55a. Abstract 218.
148. Figg WD, Dahut W, Duray P, et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888-1893.
149. Dahut WL, Arlen PM, Gulley J, et al. A randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Proc Am Soc Clin Oncol. 2002;21:183a. Abstract 730.
150. Figg WD, Arlen P, Gulley J, et al. A randomized Phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001;28(Suppl 15):62-66.
151. Dreicer R, Elson P, Klein EA, et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Proc Am Soc Clin Oncol. 2002;21:196a. Abstract 782.
152. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21(Suppl 1):S34-S41.
153. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS. 1998;9:751-755.
154. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593-2602.
155. Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 1999;13:2105-2111.
156. Govindarajan R, Maddox AM, Safar AM, et al. The efficacy of thalidomide and irinotecan in metastatic colorectal carcinoma (Phase II study). Proc Am Soc Clin Oncol. 2002;21:102b. Abstract 2222.
157. Govindarajan R. Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Huntingt). 2002;16(Suppl 3):23-26.
158. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: A Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82:812-817.
159. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000;18:2710-2717.
160. Tseng JE, Glisson BS, Khuri FR, et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001;92:2364-2373.
161. Hwu WJ, Krown SE, Menell JH, et al. Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: A Phase II trial. Proc Am Soc Clin Oncol. 2002;21:344a. Abstract 1372.
162. Danson S, Arance A, Lorigan P, et al. A randomized study of temozolomide (TMZ) alone, with interferon-α (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol. 2002;21:343a. Abstract 1369.
163. Pavlick AC, Oratz R, Bailes A, et al. A Phase II trial of DTIC with thalidomide in metastatic melanoma. Proc Am Soc Clin Oncol. 2002;21:349a. Abstract 1393.
164. Game M, Coso D, Sturgeon J, et al. Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Blood. 2001;98:365b. Abstract 5235.
165. Bertolini F, Mingrone W, Alietti A, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol. 2001;12:987-990.
166. Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology (Huntingt). 2002;16:21-24.
167. Lee SM, James LE, Mohamed-Ali V, et al. A Phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2002;21:313a. Abstract 1251.
168. Chen CS, Hillebrand D, Hill K, et al. A pilot study of celecoxib combined with escalating doses of thalidomide for treatment of unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol. 2002;21:134b. Abstract 2350.
169. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol. 2002;21:97b. Abstract 2202.
170. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Ann Oncol. 1999;10:857-859.
171. Jacobson JM, Spritzler J, Fox L, et al, for the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis. 1999;180:61-67.
172. Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial. Clin Infect Dis. 1999;28:892-894.
173. Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: Successful treatment with thalidomide. J Am Acad Dermatol. 1990;23:523-525.
174. Diz Dios P, Sopena B, Cameselle J, et al. Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers. Arch Otolaryngol Head Neck Surg. 2000;126:89-92.
175. Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis. 2001;68:201-206.
176. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126:923-927.
177. Grinspan D, Blanco GF, Aguero S. Treatment of aphthae with thalidomide. J Am Acad Dermatol. 1989;20:1060-1063.
178. Buno IJ, Huff JC, Weston WL, et al. Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol. 1998;134:827-831.
179. Nasca MR, O'Toole EA, Palicharla P, et al. Thalidomide increases human keratinocyte migration and proliferation. J Invest Dermatol. 1999;113:720-724.
180. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of
181. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53:828-832.
182. Shek LP, Lee YS, Lee BW, Lehman TJ. Thalidomide responsiveness in an infant with Behçet's syndrome. Pediatrics. 1999;103:1295-1297.
183. Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: Clinical features and treatment including thalidomide. Rheumatology. 2001;40:933-938.
184. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial. Gastroenterology. 1999;117:1271-1277.
185. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999;117:1278-1287.
186. Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results. J Pediatr Gastroenterol Nutr. 2001;32:178-181.
187. Fu CS, Conteas CN, LaRiviere MJ. Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus. AIDS Patient Care STDs. 1998;12:903-906.
188. Raufman JP, Lamps LW. Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C. Am J Gastroenterol. 2001;96:3209-3211.
189. Aboulafia DM. Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment. Clin Infect Dis. 2000;30:826-831.
190. Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol. 2000;136:1442-1443.
191. Sharpstone D, Rowbottom A, Francis N, et al. Thalidomide: A novel therapy for microsporidiosis. Gastroenterology. 1997;112:1823-1829.
192. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000;16:1345-1355.
193. Reyes-Teràn G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501-1507.
194. Gori A, Rossi MC, Marchetti G, et al. Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. AIDS. 2000;14:1859-1861.
195. Rajkumar SV. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med. 2001;161:2502-2503. Case report.
196. Lehman TJ, Striegel K, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr. 2002;140:125-127.
197. Stambe C, Wicks IP. TNFα and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet. 1998;352:544-545.
198. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol. 1989;16:158-163.
199. Breban M, Dougados M. Reply to: Lee L, Lawford R, McNeil HP. The Efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Comment on the letter by Breban et al. Arthritis Rheum. 2001;44:2457-2458.
200. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol. 2000;59:1489-1499.
201. Smithells D. Does thalidomide cause second generation birth defects? Drug Saf. 1998;19:339-341.
202. Fabro S, Smith RL, Williams RT. Toxicity and teratogenicity of optical isomers of thalidomide. Nature. 1967;215:296. Letter.
203. Haslett P, Tramontana J, Burroughs M, et al. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24:1223-1227.
204. Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med. 2000;343:972-973.
205. Williams I, Weller IV, Malni A, et al. Thalidomide hypersensitivity in AIDS. Lancet. 1991;337:436-437.
206. Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol. 1994;130:66-69.
207. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: A clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry. 1968;31:543-551.
208. Markarian Y, Wulff EA, Simpson DM. Peripheral neuropathy in HIV disease. AIDS Clin Care. 1998;10:89-98.
209. Lagueny A, Rommel A, Vignolly B, et al. Thalidomide neuropathy: An electrophysiologic study. Muscle Nerve. 1986;9:837-844.
210. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001;24:1050-1057.
211. Wulff CH, Hoyer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol. 1985;112:475-480.
212. Harland CC, Steventon GB, Marsden JR. Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol. 1995;49:1-6.
213. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol. 1984;120:338-341.
214. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
215. Camba L, Peccatori J, Pescarollo A, et al. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica. 2001;86:1108-1109.
216. Zangari M, Siegel E, Anaissie EJ, et al. Synergistic thrombogenic factors in myeloma patients treated with thalidomide. Proc Am Soc Clin Oncol. 2002;21:277a. Abstract 1106.
217. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951-1952.
218. Bennett CL, Schumok GT, Kwaan HC, et al. High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. Blood. 2001;98:863a. Abstract 3581.
219. Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002;112:412-413.
220. Fowler R, Imrie K. Thalidomide-associated hepatitis: A case report. Am J Hematol. 2001;66:300-302.
221. Passeron T, Lacour JP, Murr D, Ortonne JP. Thalidomide-induced amenorrhoea: Two cases. Br J Dermatol. 2001;144:1292-1293.
222. Iqbal N, Zayed M, Boden G. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care. 2000;23:1172-1176.